新型三级二甲基乙胺作为卡帕阿片类受体的功能选择性激动剂
Thomas O Schrader1, Kym I Lorrain1, Matthew R Nelli1
1Contineum Therapeutics, 3565 General Atomics Court, Suite 200, San Diego, CA 92121, United States.
Bioorganic & medicinal chemistry letters
|January 26, 2025
概括
新型卡帕阿片类受体 (KOR) 激动剂被开发用于选择性地激活G蛋白信号,避免β-arrestin-2. 化合物39作为中枢神经系统疾病的潜在治疗药物具有前景,提供更好的安全性和耐受性.
科学领域:
- 药用化学 医学化学
- 神经药理学神经药理学
- 药物发现 药物发现 药物发现
背景情况:
- 卡帕阿片类受体 (KOR) 激动剂正在研究中枢神经系统 (CNS) 疾病.
- 偏好G蛋白信号,而不是β-arrestin-2的招募,是提高KOR激动剂的安全性和耐受性的策略.
- 现有的KOR激动剂可能由于副作用概况而存在局限性.
研究的目的:
- 发现具有G蛋白偏差信号特征的新型KOR激动剂.
- 为了识别具有改善的代谢稳定性和对片受体 (MOR) 和片受体 (DOR) 选择性的化合物.
- 评估化合物在中枢神经系统疾病中的潜在治疗应用.
主要方法:
- 结构-活性关系 (SAR) 研究是在二乙烯胺支架上进行的.
- 用双循环异芳香物替代,产生了三级二甲基乙烯胺.
- 功能性测定测量了G蛋白激活 (GTPγS) 和β-arrestin-2招募.
- 在体外测试中评估了代谢稳定性 (肝细胞) 和P-糖蛋白 (Pgp) 流量 (MDR1-MDCK).
- 放射性配体结合试验确定了针对MOR和DOR的选择性.
主要成果:
- 三级二甲基乙胺保留了KOR激动剂活性,并显示了增强的代谢稳定性.
- 化合物39强烈激活G蛋白信号 (EC50 = 14nM,83%的Emax) 没有显著的β-arrestin-2招募 (Emax<10%).
- 化合物39表现出中度至高的内在清除和低的Pgp介导排泄.
- 化合物39对KOR比MOR (60倍) 和DOR (810倍) 具有显著的选择性.
结论:
- 化合物39是一种G蛋白偏差的KOR激动剂,具有良好的体外特性.
- 开发的化合物显示出潜在的中枢神经系统治疗药物的潜在潜力,这些治疗药物针对KOR.
- 这种偏见的激进主义方法可能会导致更安全,更耐受的基于KOR的药物.
相关概念视频
Opioid Receptors: Overview
459
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
459
Opioid Analgesics: Synthetic and Semisynthetic Opioids
212
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
212
Analgesia and Pain Management
463
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
463
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K


